Toku applies artificial-intelligence algorithms to retinal photographs, turning routine eye-exam images into a non-invasive screening tool for systemic diseases such as cardiovascular events, stroke and diabetes. The company’s platform looks for biometric markers in the retina and is designed to be compatible with widely used retinal cameras, enabling rapid deployment in optometry clinics and other care settings. Management claims that more than 80% of cardiac events and diabetes-related blindness could be prevented with earlier risk identification, a gap the technology aims to close. Proceeds from its recent financing will accelerate product development and commercialization, with strategic support from leading vision-care partners. National Vision will help integrate the software across its extensive retail network, while Topcon Healthcare will contribute data-science expertise and hardware integration. Toku ultimately envisions affordable, point-of-care retinal analytics that bridges eyecare and primary care, expanding access to potentially life-saving diagnostics.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2023